DxTerity Announces Preliminary Results from the BRAVO Study will be Presented at the 2017 ACR/ARHP Annual Meeting

LOS ANGELES, Nov. 5, 2017 /PRNewswire/ -- DxTerity, a patient-centric genomics company developing at-home genomic monitoring blood tests for immune mediated diseases, today announced that data on the BRAVO Study in which participants with rheumatoid arthritis (RA) used a combination of on-line Patient Reported Outcomes and the DxCollect® Fingerstick Collection kit to monitor disease characteristics are being presented at the 2017 ACR/ARHP Annual Meeting being held Nov. 3-8, 2017 in San Diego, CA.

Details of the poster presentation are as follows:

Title: Social Media Based, Direct-to-Patient Study Designed for Development of "From Home" Testing for Rheumatoid Arthritis Patients is Feasible and Engaged Individuals with Distinct Clinical Characteristics

Authors: K Warren, O Khalid, O Derbeneva, M Frits, J Healy, C Iannaccone, K Morampudi, N Shadick, M Weinblatt, H Wijesuriya, F Flores, R Terbrueggen

Session Title: Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

Date: Sunday, Nov. 5, 2017, 9:00 – 11:00 a.m. PT.

Location: ACR Poster Session A

Abstract # 441

The objective of the study was to investigate the feasibility of recruiting a patient cohort entirely through social media and to evaluate the quality of the genomic data collected. Cohort metrics were compared with clinical data of patients enrolled in a traditional, clinically managed study by the Brigham and Women's Hospital. The findings demonstrated that social media and molecular analysis of patient-collected fingerstick samples are viable to examine efficacy of direct-to-patient testing for RA affected individuals. The genomic RNA quality of the samples in the DxCollect fingerstick collection kit were similar to those obtained through traditional means at the Brigham and Women's Hospital despite the smaller volume, "from home" self-collection by participants. Cohorts showed differences in some clinical parameters including treatments and disease activity indicating that a direct-to-patient approach may add depth to the complex RA patient population that can be effectively monitored.

"Developing tools to lower the barriers to clinical study participation while increasing the types of patients we see in clinical studies can be an effective strategy in obtaining a diverse patient population for studies," said Bob Terbrueggen, chief executive officer and founder of DxTerity.

For more information about this presentation, please visit the ACR website at http://acrabstracts.org/. Visit DxTerity at the meeting at Booth #2316 for more info.

About Rheumatoid Arthritis:

Rheumatoid arthritis is a chronic, systemic inflammatory condition affecting an estimated 1.5 million Americans. It is often characterized by symptoms that include pain, stiffness and inflammation of the joints. 

About DxTerity:

DxTerity is a patient-centric genomics company bringing the power of real-world genomics with From-Home RNA monitoring to improving the management of immune-mediated diseases. With patented and proprietary technologies that engage patients where they live, DxTerity is increasing clinical study efficiency while transforming the management of immune-mediated disease by helping to provide a more complete picture of an individual's health. DxTerity also provides services and technologies to partner organizations including running population-scale genomic studies. For more information, please visit www.dxterity.com.

DxCollect® Fingerstick Collection Kit is for Research Use Only, not for use in diagnostic procedure.

SOURCE DxTerity